Edition:
United States

Depomed Inc (DEPO.OQ)

DEPO.OQ on NASDAQ Stock Exchange Global Select Market

14.23USD
28 Mar 2017
Change (% chg)

-- (--)
Prev Close
$14.23
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
391,255
52-wk High
$27.00
52-wk Low
$12.46

Latest Key Developments (Source: Significant Developments)

Depomed announces cooperation agreement with Starboard Value Lp
Tuesday, 28 Mar 2017 04:03pm EDT 

Depomed Inc - : Depomed announces cooperation agreement with Starboard Value Lp including CEO and board changes . Three new directors named to board . Says q1 2017 net sales estimated to be $95-$100 million- . Says James Fogarty named new chairman of boar . James Fogarty named new chairman of board . Arthur J. Higgins has joined company as president and chief executive officer and member of board of directors . Says q1 results reflect impact of previously announced realignment of company's sales force effective February 1, 2017 . Company will revise its financial guidance for year . Q1 revenue view $114.6 million -- Thomson Reuters I/B/E/S .Says resignation of James Schoeneck as president and chief executive officer and member of board of directors.  Full Article

Depomed reports Q4 loss per share $0.72
Tuesday, 21 Feb 2017 04:01pm EST 

Depomed Inc - : Depomed reports fourth quarter and full year 2016 financial results . Q4 revenue $124 million versus I/B/E/S view $123 million . Quarterly loss per share $0.72 . Quarterly non-gaap earnings per share $0.48 . Sees 2017 total revenue $490 million to $520 million . Sees 2017 non-gaap adjusted ebitda $170 to $195 million . Q4 earnings per share view $0.36 -- Thomson Reuters I/B/E/S . FY2017 earnings per share view $1.18, revenue view $516.7 million -- Thomson Reuters I/B/E/S .Recorded $43 million gaap tax expense charge related to establishment of a reserve against co's deferred tax assets during Q4 of 2016.  Full Article

Depomed announces new CAMBIA formulation
Friday, 4 Nov 2016 08:00am EDT 

Depomed Inc : Depomed announces new CAMBIA formulation .Depomed says introduction of a new formulation of CAMBIA for oral solution that contains sweetener sucralose.  Full Article

Depomed reports second quarter 2016 financial results
Wednesday, 3 Aug 2016 04:01pm EDT 

Depomed Inc : Q2 adjusted non-GAAP earnings per share $0.27 . Q2 revenue $117 million versus I/B/E/S view $117.9 million . Q2 earnings per share view $0.26 -- Thomson Reuters I/B/E/S . Depomed reports second quarter 2016 financial results . Q2 loss per share $0.17 . Sees 2016 non-GAAP adjusted ebitda $175 million to $190 million . FY2016 earnings per share view $1.20, revenue view $495.0 million -- Thomson Reuters I/B/E/S . Depomed inc says depomed is updating its 2016 financial guidance .Sees 2016 total revenue $480 million to $505 million.  Full Article

Depomed- Court order extending stay in NUCYNTA ANDA litigation
Wednesday, 18 May 2016 04:45pm EDT 

Depomed Inc : Depomed announces district court order extending stay in NUCYNTA ANDA litigation .Additional six months of patent protection is expected for these patents upon issuance of pediatric exclusivity from FDA.  Full Article

Depomed Inc revises FY 2016 revenue guidance
Thursday, 5 May 2016 04:00pm EDT 

Depomed Inc:Revising FY 2016 financial guidance for total revenue, total non-GAAP SG&A expense and total non-GAAP R&D expense.Total Revenue $490 to $520 million (Prior Guidance $485 to $525 million).Total Non-GAAP SG&A Expense $185 to $195 million.Total Non-GAAP R&D Expense $28 to $35 million.  Full Article

Depomed Inc gives FY 2016 guidance
Monday, 22 Feb 2016 04:00pm EST 

Depomed Inc:Sees Fy 2016 Total Revenue $485 to $525 million.Sees Fy 2016 Total Non-GAAP SG&A Expense $180 to $195 million.Sees Fy 2016 Total Non-GAAP R&D Expense $30 to $40 million.Sees Fy 2016 Non-GAAP Adjusted Earnings $95 to $115 million.Sees Fy 2016 Non-GAAP Adjusted EBITDA $175 to $205 million.  Full Article

Depomed Inc acquires U.S. Rights to Late-Stage, First-in-Class Pain Product from Grunenthal
Tuesday, 17 Nov 2015 04:25pm EST 

Depomed Inc:Acquires U.S. rights to late-stage, first-in-class pain product from grunenthal.Says anticipates advancing cebranopadol into phase III development for chronic lower back pain and other pain indications by 2017.Says entered into a settlement agreement with Endo Pharmaceuticals Inc.Settlement agreement grants Endo a non-exclusive patent license in the U.S., and a covenant not to Sue Outside the U.S.Settlement agreement to resolve ongoing patent litigation against Endo for alleged infringement of three of depomed's patents.Providing grünenthal witha limited covenant not to Sue Under Certain Depomed acuform® drug delivery patents and $25 million in cash.Says settlement agreement with Endo becomes effective upon the closing under the license agreement.Will also pay grünenthal royalties on net sales and one-time net sales milestones.  Full Article

Depomed Inc raises FY 2015 guidance
Monday, 9 Nov 2015 04:01pm EST 

Depomed Inc:Raises FY 2015 product sales guidance to $336 to $348 million.Raises FY 2015 non-GAAP adjusted EBITDA to $108 to $116 million, up from prior guidance of $95 to 110 million and non-GAAP adjusted earnings to $58 to $66 million, up from prior guidance of $40 to $50 million.FY 2015 revenue of $340 million and EBITDA of $87 million - Thomson Reuters I/B/E/S.  Full Article

Horizon Pharma extends offer to acquire Depomed Inc,
Monday, 26 Oct 2015 05:42pm EDT 

Horizon Pharma PLC:Extends offer to acquire Depomed Inc.Extended expiration of exchange offer to acquire shares of Depomed to 5 p.m., eastern time, on November 20, 2015.Says exchange offer was previously scheduled to expire at 5 p.m., eastern time on November 6, 2015.Says all other terms and conditions of the exchange offer remain unchanged.  Full Article

More From Around the Web

Photo

U.S. senator launches probe into five top opioid drugmakers

U.S. Democratic Senator Claire McCaskill sought on Tuesday details from the nation's top opioid drugmakers on their sales and marketing practices, as lawmakers step up efforts to tackle the country's deadly opioid crisis.